Hvsen Biotechnology Balance Sheet Health
Financial Health criteria checks 4/6
Hvsen Biotechnology has a total shareholder equity of CN¥1.5B and total debt of CN¥931.5M, which brings its debt-to-equity ratio to 61.7%. Its total assets and total liabilities are CN¥3.0B and CN¥1.5B respectively. Hvsen Biotechnology's EBIT is CN¥23.8M making its interest coverage ratio -1.6. It has cash and short-term investments of CN¥572.2M.
Key information
61.7%
Debt to equity ratio
CN¥931.50m
Debt
Interest coverage ratio | -1.6x |
Cash | CN¥572.23m |
Equity | CN¥1.51b |
Total liabilities | CN¥1.48b |
Total assets | CN¥2.99b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 300871's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥797.3M).
Long Term Liabilities: 300871's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥686.8M).
Debt to Equity History and Analysis
Debt Level: 300871's net debt to equity ratio (23.8%) is considered satisfactory.
Reducing Debt: 300871's debt to equity ratio has increased from 11.8% to 61.7% over the past 5 years.
Debt Coverage: 300871's debt is not well covered by operating cash flow (6.9%).
Interest Coverage: 300871 earns more interest than it pays, so coverage of interest payments is not a concern.